Patents by Inventor Martin A. Eglitis

Martin A. Eglitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
    Publication number: 20060134081
    Abstract: The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell. The disclosure also relates to a method for delivery of therapeutic protein molecules into the brain of a mammal, by administering to a mammal an effective amount of bone marrow-derived progenitor cells which contain a gene having a nucleic acid sequence that encodes a functional therapeutic protein. Isolated recombinant cells and a pharmaceutical composition are also provided.
    Type: Application
    Filed: January 25, 2006
    Publication date: June 22, 2006
    Inventors: Martin Eglitis, Eva Mezey, Mary Mouradian
  • Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
    Patent number: 7022321
    Abstract: The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell. The disclosure also relates to a method for delivery of therapeutic protein molecules into the brain of a mammal, by administering to a mammal an effective amount of bone marrow-derived progenitor cells which contain a gene having a nucleic acid sequence that encodes a functional therapeutic protein. Isolated recombinant cells and a pharmaceutical composition are also provided.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: April 4, 2006
    Inventors: Martin A. Eglitis, Eva Mezey, Mary Maral Mouradian
  • Vectors including foreign genes and negative selective markers
    Patent number: 6761884
    Abstract: A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: July 13, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael Blaese, W. French Anderson, Jeanne R. McLachlin, Yawen L. Chiang, Martin Eglitis
  • Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
    Publication number: 20030003087
    Abstract: The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell.
    Type: Application
    Filed: April 11, 2002
    Publication date: January 2, 2003
    Applicant: Department of Health and Human Services
    Inventors: Martin A. Eglitis, Eva Mezey, Mary Maral Mouradian
  • Vectors including foreign genes and negative selective markers
    Patent number: 5925345
    Abstract: A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 20, 1999
    Assignees: Genetic Therapy, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael Blaese, W. French Anderson, Jeanne R. McLachlin, Yawen L. Chiang, Martin Eglitis
  • Retroviral vectors
    Patent number: 5672510
    Abstract: A retroviral vector including a multiple cloning site having no greater than about 70 base pairs, and which includes at least four different enzyme restriction sites, wherein at least two of the sites have an average frequency of appearance in eukaryotic genes of less than one in 10,000 base pairs. Such vector may be employed in conjunction with a shuttle cloning vector having complementary cloning sites to accomplish transfers of genes and/or promoters between the shuttle cloning vector and the retroviral vector. Such a system provides for efficient transfer of genes and/or promoters to a retroviral vector without necessitating reconstruction of the entire retroviral vector. Also contemplated within the scope of the present invention is a retroviral vector having a 3' LTR wherein at least the promoter sequence of the 3' LTR is mutated such that the promoter sequence becomes nonfunctional.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: September 30, 1997
    Assignees: Genetic Therapy, Inc., The United States of America as represented by the Secretary Deptartment of Health and Human Services
    Inventors: Martin Eglitis, J. Anthony Thompson, W. French Anderson